Clinical pharmacology of pulmonary obstruction

Management of Acute Exacerbation of COPD

Management of Chronic Obstructive Pulmonary Disease (COPD) includes treatment of stable disease as well as management of acute exacerbations. An acute COPD exacerbation is defined as a sudden worsening of respiratory symptoms that requires additional therapy.

Treatment of an acute exacerbation includes oxygen therapy, bronchodilators, systemic corticosteroids, antibiotics, and, in some cases, ventilatory support. The main immediate goals of treatment are to ensure adequate tissue oxygenation, normalize or approximate normal blood pH, reduce airway obstruction, and treat the underlying cause of the exacerbation.

The cause of an acute exacerbation is often unclear, but most cases are associated with bacterial or viral respiratory infections. Exacerbations may also be triggered by smoking, inhalation of irritants, or increased air pollution.

In mild exacerbations, and when adequate home care is available, patients may be treated on an outpatient basis. Elderly or frail patients, those with significant comorbidities, a history of respiratory failure, or acute changes in blood gases are usually hospitalized for monitoring and treatment. Life-threatening exacerbations characterized by severe hypoxemia, acute respiratory acidosis, new arrhythmias, or progressive respiratory failure despite treatment are indications for admission to an intensive care unit.

Oxygen Therapy During Acute COPD Exacerbation

During an acute exacerbation, most patients require supplemental oxygen therapy, even if they have not previously used it. Oxygen administration may worsen hypercapnia; however, it remains necessary to correct hypoxemia. The worsening of hypercapnia is thought to be related to suppression of the hypoxic respiratory drive.

The target arterial partial pressure of oxygen (PaO₂) is approximately 60 mm Hg. Higher values usually do not provide additional benefit and increase the risk of hypercapnia. In most cases, low oxygen concentrations are sufficient. High oxygen requirements may indicate the presence of a right-to-left shunt or other conditions such as pneumonia or pulmonary edema.

In patients prone to hypercapnia, oxygen is administered via nasal cannula or a Venturi mask, which allows precise control of oxygen concentration. These patients must be monitored closely. If the patient’s condition deteriorates during treatment, with the development of severe acidemia or central nervous system depression, ventilatory support is required.

Some patients who are prescribed oxygen therapy for the first time at hospital discharge improve within 30 days and may no longer require it. Therefore, the need for long-term oxygen therapy should be reassessed 60–90 days after discharge.

Ventilatory Support During Acute Exacerbation

Noninvasive positive pressure ventilation is an alternative to invasive mechanical ventilation. It reduces the need for intubation, shortens hospital stay, and decreases mortality in patients with severe exacerbations when arterial blood pH is below 7.30 but the patient remains hemodynamically stable and is not at imminent risk of respiratory arrest.

In milder exacerbations, noninvasive ventilation has no clear benefit but may be considered if blood gas values worsen despite initial therapy or if the patient is approaching the need for invasive ventilation. In patients with marked dyspnea, hyperinflation, and increased activity of accessory respiratory muscles, positive pressure ventilation can also reduce the work of breathing.

If blood gas parameters, mental status, or respiratory muscle fatigue worsen during treatment, endotracheal intubation and mechanical ventilation are required.

Risk factors for ventilator dependence include severely reduced FEV₁, persistent severe hypoxemia or hypercapnia, marked limitation of physical activity, and poor nutritional status. For high-risk patients, treatment limits and patient preferences regarding intubation and mechanical ventilation should be discussed while the patient is still clinically stable.

High-flow nasal oxygen therapy may be used in patients who cannot tolerate noninvasive ventilation masks.

In cases requiring prolonged intubation, tracheostomy may be performed to improve patient comfort, communication, and nutrition. Appropriate multidisciplinary rehabilitation allows many patients to be successfully weaned from ventilation and return to their previous functional status.

In patients with severe chronic hypercapnia, nocturnal noninvasive ventilation after hospitalization may reduce hypercapnia and improve survival, although it does not significantly improve long-term quality of life. This decision should be made jointly with the patient.

Pharmacological Treatment of Acute COPD Exacerbation

Bronchodilators and corticosteroids should be started as early as possible together with oxygen therapy in order to reduce airway obstruction. Methylxanthines are no longer used because of their unfavorable safety profile.

Short-acting beta-2 agonists are the main medications used in the treatment of acute exacerbations. The most commonly used drug is Salbutamol. When used correctly, a metered-dose inhaler is as effective as a nebulizer. In severe, treatment-resistant cases, continuous nebulized therapy may be used.

Anticholinergic drugs, particularly Ipratropium, are administered together with or alternately with beta-2 agonists. They provide bronchodilation similar to that of beta-agonists. The role of long-acting anticholinergic drugs during acute exacerbations is not clearly defined.

Systemic corticosteroids should be given in all but very mild exacerbations. The most commonly used regimen is oral Prednisolone for 5–7 days or intravenous Methylprednisolone in more severe cases. These regimens are considered similarly effective.

Antibiotics are recommended for patients who develop purulent sputum. Broad-spectrum antibiotics targeting common oral flora are usually prescribed. The choice of treatment depends on local resistance patterns and the patient’s clinical history. In more severe or resistant cases, broader-spectrum antibiotics may be required.

Patients may be taught to recognize changes in sputum color as a sign of exacerbation and to start an antibiotic course early. In some cases, antibiotics can be avoided when C-reactive Protein levels are low.

Long-term antibiotic prophylaxis is recommended only for patients with structural lung diseases such as Bronchiectasis. Long-term use of macrolides may reduce exacerbation frequency but is associated with adverse effects.

Cough suppressants have no role in the treatment of acute COPD exacerbations. Opioids may be used very cautiously only for symptomatic treatment because they can suppress cough, worsen mental status, and cause constipation.